文献速递脊柱关节炎

古塞奇尤单抗通过复合指数评估的1年多领域有效性:COSMOS试验中TNFi应答不佳PsA患者的事后分析

Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

COSMOS试验事后分析纳入285例对1或2种TNFi应答不佳的活动性PsA患者,随机接受古塞奇尤单抗100mg或安慰剂。第24周古塞奇尤单抗组达到低疾病活动度(LDA)和缓解的复合指数比例高于安慰剂组,LDA率至第48周进一步升高。古塞奇尤单抗在多个疾病领域带来获益。

要点

  • 第24周古塞奇尤单抗组LDA达标率14.8-52.4%,安慰剂组3.1-28.1%。
  • 古塞奇尤单抗组LDA率至第48周升高,MDA达标率27.0%,PsARC应答率64.0%。
  • 安慰剂交叉至古塞奇尤单抗组第48周应答率与古塞奇尤单抗随机组相似。

核心结论

  • 古塞奇尤单抗在多个疾病领域提供显著获益,1年内达到LDA或缓解的患者比例不断增加,尽管患者既往对TNFi应答不佳。

研究设计与样本

  • IIIb期COSMOS试验事后分析,285例对1或2种TNFi应答不佳的活动性PsA成人患者随机(2:1)接受古塞奇尤单抗100mg或安慰剂。
  • 古塞奇尤单抗在第0周、第4周给药,之后每8周一次至第44周;安慰剂组在第24周交叉至古塞奇尤单抗。
  • 第24周前应用治疗失败规则,第48周前对缺失数据采用无应答者填补。

主要发现

  • 第24周,古塞奇尤单抗随机组达到低疾病活动度(LDA)复合指数终点的比例高于安慰剂随机组(14.8-52.4% vs 3.1-28.1%)。
  • 第24周,古塞奇尤单抗随机组达到缓解的复合指数终点比例为3.7-5.3%,安慰剂随机组为0.0-2.1%。
  • 古塞奇尤单抗随机组LDA率至第48周升高:DAPSA为44.4%,DAS28为47.8%,PASDAS为34.4%,GRACE为33.3%,mCPDAI为40.2%。
  • 古塞奇尤单抗随机组第48周MDA达标率为27.0%,PsARC应答率为64.0%。
  • 安慰剂交叉至古塞奇尤单抗组第48周应答率与古塞奇尤单抗随机组相似。

关键数值与推荐

  • 评估的复合指数包括DAPSA、DAS28、PsARC、PASDAS、GRACE、mCPDAI、MDA和VLDA。
  • 第24周古塞奇尤单抗随机组LDA率为14.8-52.4%,安慰剂随机组为3.1-28.1%;缓解率分别为3.7-5.3%和0.0-2.1%。
  • 第48周古塞奇尤单抗随机组DAPSA LDA率44.4%,DAS28 LDA率47.8%,PASDAS LDA率34.4%,GRACE LDA率33.3%,mCPDAI LDA率40.2%。
  • 第48周古塞奇尤单抗随机组MDA达标率27.0%,PsARC应答率64.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate guselkumab efficacy, an anti-interleukin-23p19-subunit antibody, in patients with active psoriatic arthritis (PsA) and inadequate response to 1 or 2 tumour necrosis factor inhibitors (TNFi-IR), utilizing composite indices assessing disease activity across disease domains. METHODS: In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks through W44. Patients receiving placebo crossed over to guselkumab at W24. In this post hoc analysis, composite indices evaluated included the Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score 28 (DAS28), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Disease Activity Score (PASDAS), GRAPPA Composite score (GRACE), modified Composite Psoriatic Disease Activity Index (mCPDAI), minimal disease activity (MDA), and very low disease activity (VLDA). Through W24, treatment failure rules were applied. Through W48, non-responder imputation was used for missing data. RESULTS: Greater proportions of guselkumab- than placebo-randomized patients achieved composite index endpoints relating to low disease activity (LDA; 14.8-52.4% vs 3.1-28.1%) or remission (3.7-5.3% vs 0.0-2.1%) at W24. Among guselkumab-randomized patients, LDA rates increased to W48 (DAPSA, 44.4%; DAS28, 47.8%; PASDAS, 34.4%; GRACE, 33.3%; mCPDAI, 40.2%), and 27.0% and 64.0% achieved MDA and a PsARC response, respectively. In the placebo→guselkumab crossover group, W48 response rates were similar to the guselkumab-randomized group. CONCLUSION: Guselkumab treatment provided substantial benefits across multiple disease domains, with increasing proportions of patients achieving LDA/remission over 1 year, highlighting the effectiveness of guselkumab despite previous inadequate response to TNFi.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gossec L, Baraliakos X, Aletaha D, et al. Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS. Rheumatology (Oxford). 2025. PMID: 39437003. doi:10.1093/rheumatology/keae586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。